Loading patent…
AssigneeCity of Hope
InventorsDon J. Diamond, Edwin Manuel, Fernanda V. V. Castro
Estimating the term…
In one embodiment, a single modality cancer immunotherapy regimen that includes a therapeutic composition is provided. Such a therapeutic composition may include a Salmonella strain comprising a plasmid that expresses an shRNA molecule that suppresses the expression of an immunosuppressive target and suppresses tumor growth. In some aspects, the Salmonella strain is an attenuated Salmonella typhimurium strain. In other aspects, the immunosuppressive target is STAT3, IDO1, IDO2, Arginase 1, iNOS, CTLA-4, TGF-β, IL-10, pGE2 or VEGF. In one embodiment, the immunosuppressive target is IDO1 or Arg1 and the shRNA molecule is any one of SEQ ID NO:5-14.
A single modality cancer immunotherapy regimen comprising a therapeutic composition, the composition comprising a Salmonella strain selected from the group consisting of YS1646 (ATCC #202165), RE88, SL7207, x8429, x8431 and x8468 comprising a plasmid that expresses an shRNA molecule that suppresses the expression of an immunosuppressive target IDO1 and suppresses tumor growth.
A method of treating cancer comprising administering a therapeutically effective amount of a therapeutic composition, the composition comprising an anti-immunosuppressant vector that disrupts tumor-derived immune suppression and suppresses tumor growth, wherein the anti-immunosuppressant vactor comprises an attenuated Salmonella typhimurium strain selected from the group consisting of YS1646 (ATCC #202165), RE88, SL7207, x8429, x8431, and x8468 comprising a plasmid that expresses an shRNA molecule that suppresses the expression of an immunosuppressive target IDO1 and suppresses tumor growth.
A method of suppressing tumor growth comprising intravenously administering to a subject a Salmonella strain selected from the group consisting of YS1646 (ATCC #202165), RE88, SL7207, x8429, x8431, and x8468 comprising a plasmid that expresses an shRNA molecule that suppresses the expression of an immunosuppressive target IDO1 and suppresses tumor growth.
Dependencies are inferred from the claim text.